HomeInsightsStock Comparison

Ind Swift Laboratories Ltd vs Ind Swift Ltd Stock Comparison

Ind Swift Laboratories Ltd vs Ind Swift Ltd Stock Comparison

Last Updated on: Aug 02, 2025

Key Highlights

  • The Latest Trading Price of Ind-Swift Laboratories Ltd is ₹ 107.1 as of 01 Aug 15:30.
  • The P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 0 on March 2021 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Ind-Swift Ltd changed from 1.5 on March 2023 to 0 on March 2021 . This represents a CAGR of -100.00% over 4 years.
  • The Market Cap of Ind-Swift Laboratories Ltd changed from ₹ 392.34 crore on March 2022 to ₹ 425.72 crore on March 2021 . This represents a CAGR of 1.65% over 5 yearsThe Market Cap of Ind-Swift Ltd changed from ₹ 60.61 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 years.
  • The revenue of Ind-Swift Laboratories Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 22.48 crore. This represent the decline of -100% The revenue of Ind-Swift Ltd for the Mar '25 is ₹ 426.19 crore as compare to the Dec '24 revenue of ₹ 122.96 crore. This represent the growth of 246.61%.
  • The ebitda of Ind-Swift Laboratories Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ -0.72 crore. This represent the decline of -100% The ebitda of Ind-Swift Ltd for the Mar '25 is ₹ 278.4 crore as compare to the Dec '24 ebitda of ₹ 9.98 crore. This represent the growth of 2689%.
  • The net profit of Ind-Swift Laboratories Ltd changed from ₹ 17.4 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Ind-Swift Ltd changed from ₹ 2.36 crore to ₹ 256.6 crore over 8 quarters. This represents a CAGR of 942.73% .
  • The Dividend Payout of Ind-Swift Laboratories Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Ind-Swift Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Ind-Swift Laboratories Ltd

  • Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, India.
  • The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
  • Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
  • Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
  • Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

About Ind-Swift Ltd

  • Ind-Swift Limited (ISL) is an India-based pharmaceutical company.
  • The Company is engaged in the manufacturing and marketing of pharmaceutical finished dosage.
  • The products manufactured by the company include cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics and anti-fungals. The company manufactures various dosage forms, including oral solutions and suspensions; dry syrups and hard gelatin capsules; tablets; dermatologicals comprising creams, ointments, and gels; eye and ear drops; and injectables.
  • The company, through their different divisions, markets formulations focusing on the needs of various therapeutic segments, such as diabetology, cardiovascular, anesthesiology, oncology, ophthalmology, neuropsychiatry, gynecology, pediatric, ENT, surgery, internal medicine, dermatology, urology, cardiology, and dental specialty.

Ind-Swift Laboratories Ltd News Hub

News

Ind-Swift Laboratories to convene board meeting

Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 11 ...

Read more

02 Aug 2025 10:09

News

Ind-Swift Laboratories schedules board meeting

Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 30 ...

Read more

24 May 2025 18:25

News

Ind-Swift Laboratories adjourns board meeting

Ind-Swift Laboratories has adjourned the meeting of the Board of Directors which was sched...

Read more

14 Feb 2025 11:01

News

Ind-Swift Laboratories announces cessation of director

Ind-Swift Laboratories announced the cessation of Dr. Ashwani Kumar Vig as Independent Dir...

Read more

13 Feb 2025 19:26

News

Ind-Swift Laboratories adjourns board meeting

Ind-Swift Laboratories has adjourned the meeting of the Board of Directors which was sched...

Read more

13 Feb 2025 11:33

News

Ind-Swift Laboratories to announce Quarterly Result

Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 12 ...

Read more

07 Feb 2025 16:48

Ind-Swift Ltd News Hub

News

Ind-Swift Ltd leads gainers in 'B' group

Jayaswal Neco Industries Ltd, Aarti Drugs Ltd, Sampann Utpadan India Ltd and Soma Textiles...

Read more

15 Jul 2025 12:15

News

Ind-Swift to discuss results

Ind-Swift will hold a meeting of the Board of Directors of the Company on 25 June 2025. Po...

Read more

20 Jun 2025 10:07

News

Ind-Swift to convene board meeting

Ind-Swift will hold a meeting of the Board of Directors of the Company on 30 May 2025. Pow...

Read more

24 May 2025 17:38

News

Ind-Swift to conduct board meeting

Ind-Swift will hold a meeting of the Board of Directors of the Company on 11 February 2025...

Read more

07 Feb 2025 16:29

News

Ind-Swift EGM scheduled

Ind-Swift announced that an Extra Ordinary General Meeting (EGM) of the Company will be he...

Read more

21 Jan 2025 14:05

News

Ind-Swift to conduct board meeting

Ind-Swift will hold a meeting of the Board of Directors of the Company on 14 November 2024...

Read more

08 Nov 2024 16:42

SWOT Analysis Of Ind-Swift Laboratories Ltd

Strength

5

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Ind-Swift Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Ind-Swift Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Ind-Swift Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Ind-Swift Laboratories Ltd and Ind-Swift Ltd

Which company has a larger market capitalization, Ind-Swift Laboratories Ltd or Ind-Swift Ltd?

Market cap of Ind-Swift Laboratories Ltd is 649 Cr while Market cap of Ind-Swift Ltd is 90 Cr

What are the key factors driving the stock performance of Ind-Swift Laboratories Ltd and Ind-Swift Ltd?

The stock performance of Ind-Swift Laboratories Ltd and Ind-Swift Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ind-Swift Laboratories Ltd and Ind-Swift Ltd?

As of August 2, 2025, the Ind-Swift Laboratories Ltd stock price is INR ₹107.1. On the other hand, Ind-Swift Ltd stock price is INR ₹16.68.

How do dividend payouts of Ind-Swift Laboratories Ltd and Ind-Swift Ltd compare?

To compare the dividend payouts of Ind-Swift Laboratories Ltd and Ind-Swift Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions